This site is intended for health professionals only

Published on 28 October 2010

Share this story:
Twitter
LinkedIn

AstraZeneca reports falling profits

teaser

Third quarter profits at AstraZeneca fell by 27% as it reeled from a sizeable product liability litigation bill for an anti-psychotic drug.

The company took nearly half a billion dollars in charges for product liability litigation on Seroquel, it confirmed.

Net profit fell to $1.55 billion (£983 million) from $2.12 billion in the previous year, while revenue fell 3.7% to $7.9 billion.

AstraZeneca said the results for the third quarter included a charge of $473 million for ongoing and future settlements of product liability claims involving the anti-psychotic drug Seroquel. It is the company’s second biggest selling drug.

It faces accusations that Seroquel caused diabetes and other harmful effects to some patients.

Copyright Press Association 2010

AstraZeneca



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn